Both biofluid-based staging systems appeared to perform relatively similar on extreme classification groups, that is Aβ- vs AD, A-T- vs A+T+ , tau-PET Braak 0 vs V-VI, and MT−/NC− vs MT+/NC+ (Fig. 2). The gene discussed is MAPT; the disease is Alzheimer disease.